Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt 1.01
EBS's Cash-to-Debt is ranked lower than
81% of the 864 Companies
in the Global Biotechnology industry.

( Industry Median: 53.59 vs. EBS: 1.01 )
Ranked among companies with meaningful Cash-to-Debt only.
EBS' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.53  Med: 2.04 Max: No Debt
Current: 1.01
Equity-to-Asset 0.62
EBS's Equity-to-Asset is ranked lower than
54% of the 635 Companies
in the Global Biotechnology industry.

( Industry Median: 0.65 vs. EBS: 0.62 )
Ranked among companies with meaningful Equity-to-Asset only.
EBS' s Equity-to-Asset Range Over the Past 10 Years
Min: -1.27  Med: 0.63 Max: 0.78
Current: 0.62
-1.27
0.78
Interest Coverage 10.68
EBS's Interest Coverage is ranked lower than
85% of the 490 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. EBS: 10.68 )
Ranked among companies with meaningful Interest Coverage only.
EBS' s Interest Coverage Range Over the Past 10 Years
Min: 10.68  Med: 2815.62 Max: N/A
Current: 10.68
Piotroski F-Score: 4
Altman Z-Score: 3.55
Beneish M-Score: -2.51
WACC vs ROIC
11.24%
8.66%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating Margin % 16.04
EBS's Operating Margin % is ranked higher than
85% of the 661 Companies
in the Global Biotechnology industry.

( Industry Median: -97.80 vs. EBS: 16.04 )
Ranked among companies with meaningful Operating Margin % only.
EBS' s Operating Margin % Range Over the Past 10 Years
Min: 10.63  Med: 17.6 Max: 28.92
Current: 16.04
10.63
28.92
Net Margin % 10.21
EBS's Net Margin % is ranked higher than
82% of the 661 Companies
in the Global Biotechnology industry.

( Industry Median: -83.37 vs. EBS: 10.21 )
Ranked among companies with meaningful Net Margin % only.
EBS' s Net Margin % Range Over the Past 10 Years
Min: 8.35  Med: 11.09 Max: 18.07
Current: 10.21
8.35
18.07
ROE % 8.24
EBS's ROE % is ranked higher than
85% of the 773 Companies
in the Global Biotechnology industry.

( Industry Median: -39.29 vs. EBS: 8.24 )
Ranked among companies with meaningful ROE % only.
EBS' s ROE % Range Over the Past 10 Years
Min: 5.5  Med: 9.3 Max: 16.93
Current: 8.24
5.5
16.93
ROA % 5.14
EBS's ROA % is ranked higher than
86% of the 870 Companies
in the Global Biotechnology industry.

( Industry Median: -33.51 vs. EBS: 5.14 )
Ranked among companies with meaningful ROA % only.
EBS' s ROA % Range Over the Past 10 Years
Min: 4.23  Med: 5.8 Max: 12.24
Current: 5.14
4.23
12.24
ROC (Joel Greenblatt) % 18.21
EBS's ROC (Joel Greenblatt) % is ranked higher than
85% of the 827 Companies
in the Global Biotechnology industry.

( Industry Median: -476.30 vs. EBS: 18.21 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
EBS' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 11.5  Med: 24.3 Max: 41.28
Current: 18.21
11.5
41.28
3-Year Revenue Growth Rate 5.20
EBS's 3-Year Revenue Growth Rate is ranked higher than
51% of the 485 Companies
in the Global Biotechnology industry.

( Industry Median: 4.80 vs. EBS: 5.20 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
EBS' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -1.1  Med: 8.8 Max: 31.3
Current: 5.2
-1.1
31.3
3-Year EBITDA Growth Rate 20.50
EBS's 3-Year EBITDA Growth Rate is ranked higher than
71% of the 515 Companies
in the Global Biotechnology industry.

( Industry Median: 0.20 vs. EBS: 20.50 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
EBS' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: 0.4 Max: 46.8
Current: 20.5
0
46.8
3-Year EPS without NRI Growth Rate 16.70
EBS's 3-Year EPS without NRI Growth Rate is ranked higher than
71% of the 501 Companies
in the Global Biotechnology industry.

( Industry Median: -2.80 vs. EBS: 16.70 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
EBS' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -26.7  Med: 6.65 Max: 61.7
Current: 16.7
-26.7
61.7
GuruFocus has detected 3 Warning Signs with Emergent BioSolutions Inc $EBS.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» EBS's 10-Y Financials

Financials (Next Earnings Date: 2017-05-24 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

EBS Guru Trades in Q1 2016

Jim Simons 1,112,811 sh (+16.94%)
Ken Fisher 457,742 sh (unchged)
Joel Greenblatt 443,728 sh (-0.70%)
Paul Tudor Jones 24,632 sh (-8.08%)
» More
Q2 2016

EBS Guru Trades in Q2 2016

Jim Simons 1,274,211 sh (+14.50%)
Joel Greenblatt 465,311 sh (+4.86%)
Ken Fisher 467,770 sh (+2.19%)
Paul Tudor Jones 16,200 sh (-34.23%)
» More
Q3 2016

EBS Guru Trades in Q3 2016

Paul Tudor Jones Sold Out
Ken Fisher 453,870 sh (-2.97%)
Jim Simons 1,178,111 sh (-7.54%)
Joel Greenblatt 242,516 sh (-47.88%)
» More
Q4 2016

EBS Guru Trades in Q4 2016

Paul Tudor Jones 9,700 sh (New)
Ken Fisher 418,270 sh (-7.84%)
Jim Simons 883,511 sh (-25.01%)
Joel Greenblatt 165,519 sh (-31.75%)
» More
» Details

Insider Trades

Latest Guru Trades with EBS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:RGEN, NAS:ACOR, NAS:LOXO, NAS:AIMT, NAS:CORT, NAS:XNCR, NAS:CHRS, NAS:ALDR, OTCPK:BVNRY, OTCPK:GNFTF, NAS:FWP, NAS:FPRX, NAS:FOLD, NAS:XLRN, OTCPK:PFSCF, OTCPK:BPMUF, NAS:EPZM, OTCPK:AKBLF, NAS:INSM, OTCPK:GENSF » details
Traded in other countries:ER4.Germany,
Emergent BioSolutions Inc is a specialty biopharmaceutical company operating in two divisions: Biodefense and Biosciences. Its products include BioThrax, BAT, Anthrasil, VIGIV, RSDL, NuThrax, PreviThrax and GC-072.

Emergent BioSolutions is a global biotechnology company that offers biopharmaceutical products to healthcare providers and governments. The company has two operating divisions: biodefense and biosciences. Its specialty biodefense division focuses on countermeasures that address public health threats. The U.S. government is the primary purchaser of these products and often provides substantial funding for their development. Emergent's biosciences business is primarily focused on hematology and oncology therapeutics, with a secondary focus on transplantation, infectious disease, and autoimmunity.

Ratios

vs
industry
vs
history
PE Ratio 27.99
EBS's PE Ratio is ranked higher than
53% of the 285 Companies
in the Global Biotechnology industry.

( Industry Median: 28.64 vs. EBS: 27.99 )
Ranked among companies with meaningful PE Ratio only.
EBS' s PE Ratio Range Over the Past 10 Years
Min: 5.26  Med: 21.17 Max: 67.2
Current: 27.99
5.26
67.2
Forward PE Ratio 18.73
EBS's Forward PE Ratio is ranked higher than
58% of the 84 Companies
in the Global Biotechnology industry.

( Industry Median: 20.12 vs. EBS: 18.73 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 31.60
EBS's PE Ratio without NRI is ranked lower than
52% of the 259 Companies
in the Global Biotechnology industry.

( Industry Median: 28.10 vs. EBS: 31.60 )
Ranked among companies with meaningful PE Ratio without NRI only.
EBS' s PE Ratio without NRI Range Over the Past 10 Years
Min: 5.26  Med: 20.44 Max: 67.2
Current: 31.6
5.26
67.2
Price-to-Owner-Earnings 506.57
EBS's Price-to-Owner-Earnings is ranked lower than
96% of the 139 Companies
in the Global Biotechnology industry.

( Industry Median: 31.38 vs. EBS: 506.57 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
EBS' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 5.9  Med: 37.7 Max: 1470
Current: 506.57
5.9
1470
PB Ratio 1.97
EBS's PB Ratio is ranked higher than
74% of the 1091 Companies
in the Global Biotechnology industry.

( Industry Median: 3.76 vs. EBS: 1.97 )
Ranked among companies with meaningful PB Ratio only.
EBS' s PB Ratio Range Over the Past 10 Years
Min: 0.8  Med: 1.8 Max: 3.61
Current: 1.97
0.8
3.61
PS Ratio 2.73
EBS's PS Ratio is ranked higher than
84% of the 854 Companies
in the Global Biotechnology industry.

( Industry Median: 12.99 vs. EBS: 2.73 )
Ranked among companies with meaningful PS Ratio only.
EBS' s PS Ratio Range Over the Past 10 Years
Min: 0.71  Med: 2.19 Max: 4.07
Current: 2.73
0.71
4.07
Price-to-Operating-Cash-Flow 26.95
EBS's Price-to-Operating-Cash-Flow is ranked lower than
61% of the 232 Companies
in the Global Biotechnology industry.

( Industry Median: 20.83 vs. EBS: 26.95 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
EBS' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 2.45  Med: 13.29 Max: 102.3
Current: 26.95
2.45
102.3
EV-to-EBIT 14.39
EBS's EV-to-EBIT is ranked higher than
62% of the 320 Companies
in the Global Biotechnology industry.

( Industry Median: 21.73 vs. EBS: 14.39 )
Ranked among companies with meaningful EV-to-EBIT only.
EBS' s EV-to-EBIT Range Over the Past 10 Years
Min: 1.7  Med: 12.2 Max: 38.3
Current: 14.39
1.7
38.3
EV-to-EBITDA 9.86
EBS's EV-to-EBITDA is ranked higher than
70% of the 355 Companies
in the Global Biotechnology industry.

( Industry Median: 16.79 vs. EBS: 9.86 )
Ranked among companies with meaningful EV-to-EBITDA only.
EBS' s EV-to-EBITDA Range Over the Past 10 Years
Min: 1.5  Med: 9.4 Max: 22
Current: 9.86
1.5
22
PEG Ratio 1.10
EBS's PEG Ratio is ranked higher than
66% of the 94 Companies
in the Global Biotechnology industry.

( Industry Median: 1.96 vs. EBS: 1.10 )
Ranked among companies with meaningful PEG Ratio only.
EBS' s PEG Ratio Range Over the Past 10 Years
Min: 0.57  Med: 1.96 Max: 85.06
Current: 1.1
0.57
85.06
Shiller PE Ratio 29.90
EBS's Shiller PE Ratio is ranked higher than
74% of the 54 Companies
in the Global Biotechnology industry.

( Industry Median: 52.28 vs. EBS: 29.90 )
Ranked among companies with meaningful Shiller PE Ratio only.
EBS' s Shiller PE Ratio Range Over the Past 10 Years
Min: 15.28  Med: 29.02 Max: 40.87
Current: 29.9
15.28
40.87
Current Ratio 4.82
EBS's Current Ratio is ranked higher than
57% of the 838 Companies
in the Global Biotechnology industry.

( Industry Median: 4.03 vs. EBS: 4.82 )
Ranked among companies with meaningful Current Ratio only.
EBS' s Current Ratio Range Over the Past 10 Years
Min: 1.22  Med: 3.54 Max: 5.4
Current: 4.82
1.22
5.4
Quick Ratio 4.12
EBS's Quick Ratio is ranked higher than
53% of the 838 Companies
in the Global Biotechnology industry.

( Industry Median: 3.74 vs. EBS: 4.12 )
Ranked among companies with meaningful Quick Ratio only.
EBS' s Quick Ratio Range Over the Past 10 Years
Min: 0.83  Med: 3.3 Max: 4.78
Current: 4.12
0.83
4.78
Days Inventory 206.20
EBS's Days Inventory is ranked lower than
70% of the 384 Companies
in the Global Biotechnology industry.

( Industry Median: 132.21 vs. EBS: 206.20 )
Ranked among companies with meaningful Days Inventory only.
EBS' s Days Inventory Range Over the Past 10 Years
Min: 87.55  Med: 134.7 Max: 214.89
Current: 206.2
87.55
214.89
Days Sales Outstanding 99.68
EBS's Days Sales Outstanding is ranked lower than
72% of the 535 Companies
in the Global Biotechnology industry.

( Industry Median: 59.11 vs. EBS: 99.68 )
Ranked among companies with meaningful Days Sales Outstanding only.
EBS' s Days Sales Outstanding Range Over the Past 10 Years
Min: 36.05  Med: 69.18 Max: 124.36
Current: 99.68
36.05
124.36
Days Payable 89.10
EBS's Days Payable is ranked higher than
63% of the 353 Companies
in the Global Biotechnology industry.

( Industry Median: 58.37 vs. EBS: 89.10 )
Ranked among companies with meaningful Days Payable only.
EBS' s Days Payable Range Over the Past 10 Years
Min: 89.1  Med: 162.25 Max: 350.8
Current: 89.1
89.1
350.8

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -3.40
EBS's 3-Year Average Share Buyback Ratio is ranked higher than
79% of the 563 Companies
in the Global Biotechnology industry.

( Industry Median: -10.90 vs. EBS: -3.40 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
EBS' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -13.3  Med: -3.8 Max: -1.5
Current: -3.4
-13.3
-1.5

Valuation & Return

vs
industry
vs
history
Price-to-Net-Current-Asset-Value 8.72
EBS's Price-to-Net-Current-Asset-Value is ranked lower than
67% of the 870 Companies
in the Global Biotechnology industry.

( Industry Median: 5.79 vs. EBS: 8.72 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
EBS' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 3.39  Med: 6.13 Max: 20.74
Current: 8.72
3.39
20.74
Price-to-Tangible-Book 2.28
EBS's Price-to-Tangible-Book is ranked higher than
75% of the 1017 Companies
in the Global Biotechnology industry.

( Industry Median: 4.44 vs. EBS: 2.28 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
EBS' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.83  Med: 2.1 Max: 3.7
Current: 2.28
0.83
3.7
Price-to-Intrinsic-Value-Projected-FCF 2.42
EBS's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
64% of the 204 Companies
in the Global Biotechnology industry.

( Industry Median: 3.58 vs. EBS: 2.42 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
EBS' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 1.45  Med: 1.7 Max: 2.7
Current: 2.42
1.45
2.7
Price-to-Median-PS-Value 1.24
EBS's Price-to-Median-PS-Value is ranked lower than
64% of the 750 Companies
in the Global Biotechnology industry.

( Industry Median: 1.02 vs. EBS: 1.24 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
EBS' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.35  Med: 1.14 Max: 1.91
Current: 1.24
0.35
1.91
Price-to-Peter-Lynch-Fair-Value 1.34
EBS's Price-to-Peter-Lynch-Fair-Value is ranked higher than
65% of the 77 Companies
in the Global Biotechnology industry.

( Industry Median: 1.64 vs. EBS: 1.34 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
EBS' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.57  Med: 1.49 Max: 3.1
Current: 1.34
0.57
3.1
Price-to-Graham-Number 1.79
EBS's Price-to-Graham-Number is ranked higher than
70% of the 197 Companies
in the Global Biotechnology industry.

( Industry Median: 2.57 vs. EBS: 1.79 )
Ranked among companies with meaningful Price-to-Graham-Number only.
EBS' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 0.48  Med: 1.24 Max: 2.44
Current: 1.79
0.48
2.44
Earnings Yield (Greenblatt) % 6.93
EBS's Earnings Yield (Greenblatt) % is ranked higher than
90% of the 1273 Companies
in the Global Biotechnology industry.

( Industry Median: -8.24 vs. EBS: 6.93 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
EBS' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 2.6  Med: 8.2 Max: 59.3
Current: 6.93
2.6
59.3
Forward Rate of Return (Yacktman) % 25.06
EBS's Forward Rate of Return (Yacktman) % is ranked higher than
67% of the 125 Companies
in the Global Biotechnology industry.

( Industry Median: 15.69 vs. EBS: 25.06 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
EBS' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -13.5  Med: 2.5 Max: 29.1
Current: 25.06
-13.5
29.1

More Statistics

Revenue (TTM) (Mil) $507.1
EPS (TTM) $ 1.05
Beta1.45
Short Percentage of Float11.14%
52-Week Range $24.47 - 41.91
Shares Outstanding (Mil)40.69

Analyst Estimate

Dec17 Dec18
Revenue (Mil $) 511 526
EPS ($) 1.57 1.98
EPS without NRI ($) 1.57 1.98
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for EBS

Headlines

Articles On GuruFocus.com
Weekly CEO Sales Highlight: Realpage, Anadigics, Emergent BioSolutions, ScanSource Jan 03 2016 
Emergent BioSolutions Inc. Reports Operating Results (10-Q) Nov 05 2010 
Emergent BioSolutions Inc. Reports Operating Results (10-Q) Aug 06 2010 
Emergent BioSolutions Inc. (EBS) President & COO Daniel Abdun-nabi sells 18,150 Shares Jul 30 2010 
Weekly CEO Sells Highlight: Yum! Brands Inc, Marchex Inc, iGate Corp, and Emergent BioSolutions Inc. Jul 25 2010 
Emergent BioSolutions Inc. (EBS) CEO and Chairman, 10% Owner Fuad El-hibri sells 18,800 Shares Jul 23 2010 
Emergent BioSolutions Inc. (EBS) CEO and Chairman, 10% Owner Fuad El-hibri sells 130,100 Shares Jul 22 2010 
Emergent BioSolutions Inc. (EBS) CEO and Chairman, 10% Owner Fuad El-hibri sells 84,433 Shares Jul 19 2010 
Emergent BioSolutions Inc. (EBS) CEO and Chairman, 10% Owner Fuad El-hibri sells 52,000 Shares May 14 2010 
Emergent BioSolutions Inc. Reports Operating Results (10-Q) May 06 2010 

More From Other Websites
Emergent BioSolutions, Inc. breached its 50 day moving average in a Bearish Manner : EBS-US : March... Mar 20 2017
Emergent BioSolutions gets $100 million anthrax contract from feds Mar 20 2017
EMERGENT BIOSOLUTIONS INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial... Mar 17 2017
Emergent BioSolutions Awarded $100 Million BARDA Contract for BioThrax Deliveries to the Strategic... Mar 17 2017
Local drug company stocks react to Trump's proposed cuts to NIH, FDA Mar 16 2017
Blog Coverage Galapagos Announced New Phase-II Studies Led by Filgotinib Collaboration Partner... Mar 13 2017
Emergent BioSolutions, Inc. breached its 50 day moving average in a Bullish Manner : EBS-US : March... Mar 09 2017
EMERGENT BIOSOLUTIONS INC. Financials Mar 04 2017
Emergent BioSolutions, Inc. :EBS-US: Earnings Analysis: 2016 By the Numbers : March 2, 2017 Mar 02 2017
EMERGENT BIOSOLUTIONS INC. Files SEC form 10-K, Annual Report Feb 28 2017
Emergent BioSolutions, Inc. :EBS-US: Earnings Analysis: Q4, 2016 By the Numbers : February 27, 2017 Feb 27 2017
Emergent (EBS) Beats Earnings, Revenue Estimates in Q4 Feb 24 2017
Edited Transcript of EBS earnings conference call or presentation 23-Feb-17 10:00pm GMT Feb 23 2017
Emergent Biosolutions posts 4Q profit Feb 23 2017
Emergent Biosolutions posts 4Q profit Feb 23 2017
EMERGENT BIOSOLUTIONS INC. Files SEC form 8-K, Results of Operations and Financial Condition,... Feb 23 2017
Emergent BioSolutions Inc Earnings Call scheduled for 5:00 pm ET today Feb 23 2017
Emergent BioSolutions Reports Fourth Quarter and Twelve Months 2016 Financial Results; Reaffirms... Feb 23 2017
Q4 2016 Emergent BioSolutions Inc Earnings Release - After Market Close Feb 23 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)